Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 576
- Registration Number
- NCT00333151
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Windsor, Canada
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 618
- Registration Number
- NCT00331604
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 584
- Registration Number
- NCT00331851
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Phase 3
Withdrawn
- Conditions
- TraumaAcquired Bleeding Disorder
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00323570
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Madison, Wisconsin, United States
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 596
- Registration Number
- NCT00322257
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Vancouver, Canada
Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 289
- Registration Number
- NCT00318786
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1041
- Registration Number
- NCT00318422
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1091
- Registration Number
- NCT00318461
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sunbury on Thames, United Kingdom
The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00313742
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00313001
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath